Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients

Abstract

To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine. Forty patients with primary NHL in the small and large intestine were studied retrospectively. All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001. Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients. Ileum was the most commonly involved site (8 of 14 patients, 57.1%), followed by jejunum (2 of 14 patients, 14.3%) and duodenum (1 of 14 patients, 7.1%). Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients. The ileocaecal region has the highest involved rate (13 of 25 patients, 52.0%), followed by colon (7 of 25 patients, 28.0%) and rectum (3 of 25 patients, 12.0%). Compared with surgery alone, post-operation chemotherapy or chemoradiotherapy can significantly improve DLBCL patients' event-free survival (EFS). However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma. B-cell lymphoma is the most common pathological type of intestinal lymphomas. Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.

Severe Cryptogenic Multifocal Ulcerous Stenosing Enteritis. A Report of Three Cases and Review of the Literature

“…Not only polypoid and diffuse types of this disease, but also the ulcerative one can be detected in the small bowel (50). Usually either diffuse large B cell lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma are confirmed by histological methods (31).…”

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone

“…[1][2][3] Considerable information on primary gastric DLBCL is available, but there are insufficient data on the clinical features and outcomes of primary intestinal DLBCL because it is usually studied as a subgroup of GI lymphomas. 1,[3][4][5] Although a few reports focusing on primary intestinal DLBCL have been published, [6][7][8][9] the sample sizes were small, and the optimal treatment strategies specific for primary intestinal DLBCL have not been established. Various treatment approaches have been tried, such as systemic chemotherapy similar to that used to treat nodal DLBCL and primary surgical resection of intestinal lesions and postoperative chemotherapy.…”

Amebiasis Masquerading Colonic Lymphoma in an Intestinal Intussusception Patient

“…Intussusception is very rarely seen in intestinal lymphoma. The most common type of lymphoma causing intussusception is diffuse B-cell lymphoma [12].…”